Colon-specific Prodrugs of 5-radioiodo-2′-deoxyuridine

Janina Baranowska-Kortylewicz, Z. P. Kortylewicz, D. Hoffman, A. Winoto, J. Lai, G. V. Dalrymple

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Two glycoside-based prodrugs, 125IUdR-5′-β-D-glucopyranoside and 125IUdR-5′-β-D-galactopyranoside, were synthesized. This selection was dictated by the abundance of appropriate enzymes in the GI tract of mice and similar levels of β-D-glycosidases in human and rodent large intestine. Studies to establish the ability of colonic microflora to release 125IUdR were conducted in vitro and in Swiss Webster mice. Both prodrugs released 125IUdR in the presence of the corresponding enzymes or the GI content homogenates in vitro, and in vivo. Luminal enzymes in the proximal and distal small intestine in mice degraded less than 10% of each prodrug whereas enzymes from the colonic/caecal lumen of mice released nearly 100% of 125IUdR. 125IUdR freed by bacterial glycosidases was stable in the GI content. No significant amounts of other metabolites or deiodination products were observed. Total radioactivity recovered as by-products was less than 10%. The efflux of prodrugs from the GI tract after oral administration in mice was slow and limited. Unlike 125IUdR, prodrugs were not dehalogenated in vivo as indicated by biodistribution and imaging studies.

Original languageEnglish (US)
Pages (from-to)959-964
Number of pages6
JournalActa Oncologica
Volume35
Issue number7
DOIs
StatePublished - Jan 1 1996

Fingerprint

Deoxyuridine
Prodrugs
Colon
Gastrointestinal Contents
Glycoside Hydrolases
Enzymes
Gastrointestinal Tract
Large Intestine
Glycosides
Galactose
Radioactivity
Small Intestine
Oral Administration
Rodentia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Baranowska-Kortylewicz, J., Kortylewicz, Z. P., Hoffman, D., Winoto, A., Lai, J., & Dalrymple, G. V. (1996). Colon-specific Prodrugs of 5-radioiodo-2′-deoxyuridine. Acta Oncologica, 35(7), 959-964. https://doi.org/10.3109/02841869609104052

Colon-specific Prodrugs of 5-radioiodo-2′-deoxyuridine. / Baranowska-Kortylewicz, Janina; Kortylewicz, Z. P.; Hoffman, D.; Winoto, A.; Lai, J.; Dalrymple, G. V.

In: Acta Oncologica, Vol. 35, No. 7, 01.01.1996, p. 959-964.

Research output: Contribution to journalArticle

Baranowska-Kortylewicz, J, Kortylewicz, ZP, Hoffman, D, Winoto, A, Lai, J & Dalrymple, GV 1996, 'Colon-specific Prodrugs of 5-radioiodo-2′-deoxyuridine', Acta Oncologica, vol. 35, no. 7, pp. 959-964. https://doi.org/10.3109/02841869609104052
Baranowska-Kortylewicz, Janina ; Kortylewicz, Z. P. ; Hoffman, D. ; Winoto, A. ; Lai, J. ; Dalrymple, G. V. / Colon-specific Prodrugs of 5-radioiodo-2′-deoxyuridine. In: Acta Oncologica. 1996 ; Vol. 35, No. 7. pp. 959-964.
@article{cc31b3a6f90948019f3cc9a6c6b689e3,
title = "Colon-specific Prodrugs of 5-radioiodo-2′-deoxyuridine",
abstract = "Two glycoside-based prodrugs, 125IUdR-5′-β-D-glucopyranoside and 125IUdR-5′-β-D-galactopyranoside, were synthesized. This selection was dictated by the abundance of appropriate enzymes in the GI tract of mice and similar levels of β-D-glycosidases in human and rodent large intestine. Studies to establish the ability of colonic microflora to release 125IUdR were conducted in vitro and in Swiss Webster mice. Both prodrugs released 125IUdR in the presence of the corresponding enzymes or the GI content homogenates in vitro, and in vivo. Luminal enzymes in the proximal and distal small intestine in mice degraded less than 10{\%} of each prodrug whereas enzymes from the colonic/caecal lumen of mice released nearly 100{\%} of 125IUdR. 125IUdR freed by bacterial glycosidases was stable in the GI content. No significant amounts of other metabolites or deiodination products were observed. Total radioactivity recovered as by-products was less than 10{\%}. The efflux of prodrugs from the GI tract after oral administration in mice was slow and limited. Unlike 125IUdR, prodrugs were not dehalogenated in vivo as indicated by biodistribution and imaging studies.",
author = "Janina Baranowska-Kortylewicz and Kortylewicz, {Z. P.} and D. Hoffman and A. Winoto and J. Lai and Dalrymple, {G. V.}",
year = "1996",
month = "1",
day = "1",
doi = "10.3109/02841869609104052",
language = "English (US)",
volume = "35",
pages = "959--964",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Colon-specific Prodrugs of 5-radioiodo-2′-deoxyuridine

AU - Baranowska-Kortylewicz, Janina

AU - Kortylewicz, Z. P.

AU - Hoffman, D.

AU - Winoto, A.

AU - Lai, J.

AU - Dalrymple, G. V.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Two glycoside-based prodrugs, 125IUdR-5′-β-D-glucopyranoside and 125IUdR-5′-β-D-galactopyranoside, were synthesized. This selection was dictated by the abundance of appropriate enzymes in the GI tract of mice and similar levels of β-D-glycosidases in human and rodent large intestine. Studies to establish the ability of colonic microflora to release 125IUdR were conducted in vitro and in Swiss Webster mice. Both prodrugs released 125IUdR in the presence of the corresponding enzymes or the GI content homogenates in vitro, and in vivo. Luminal enzymes in the proximal and distal small intestine in mice degraded less than 10% of each prodrug whereas enzymes from the colonic/caecal lumen of mice released nearly 100% of 125IUdR. 125IUdR freed by bacterial glycosidases was stable in the GI content. No significant amounts of other metabolites or deiodination products were observed. Total radioactivity recovered as by-products was less than 10%. The efflux of prodrugs from the GI tract after oral administration in mice was slow and limited. Unlike 125IUdR, prodrugs were not dehalogenated in vivo as indicated by biodistribution and imaging studies.

AB - Two glycoside-based prodrugs, 125IUdR-5′-β-D-glucopyranoside and 125IUdR-5′-β-D-galactopyranoside, were synthesized. This selection was dictated by the abundance of appropriate enzymes in the GI tract of mice and similar levels of β-D-glycosidases in human and rodent large intestine. Studies to establish the ability of colonic microflora to release 125IUdR were conducted in vitro and in Swiss Webster mice. Both prodrugs released 125IUdR in the presence of the corresponding enzymes or the GI content homogenates in vitro, and in vivo. Luminal enzymes in the proximal and distal small intestine in mice degraded less than 10% of each prodrug whereas enzymes from the colonic/caecal lumen of mice released nearly 100% of 125IUdR. 125IUdR freed by bacterial glycosidases was stable in the GI content. No significant amounts of other metabolites or deiodination products were observed. Total radioactivity recovered as by-products was less than 10%. The efflux of prodrugs from the GI tract after oral administration in mice was slow and limited. Unlike 125IUdR, prodrugs were not dehalogenated in vivo as indicated by biodistribution and imaging studies.

UR - http://www.scopus.com/inward/record.url?scp=0030472378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030472378&partnerID=8YFLogxK

U2 - 10.3109/02841869609104052

DO - 10.3109/02841869609104052

M3 - Article

C2 - 9004778

AN - SCOPUS:0030472378

VL - 35

SP - 959

EP - 964

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 7

ER -